Prof. Changfa Qu 曲昌发
Chief Physician, Professor
Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of lung, esophageal, cardia, and mediastinal tumors. Expertise in minimally invasive surgery, bronchial sleeve resection, pneumonectomy, and targeted therapies including radioimmunotherapy.
Dr. Qu earned an MD (2004) and completed postdoctoral work (2006) at the University of New South Wales, Australia. After working in Europe and the US, Dr. Qu joined Harbin Medical University Cancer Hospital in 1985. Current roles include Director of Lung Ward II and Professor. Research focuses on targeted tumor therapy and surgical outcomes.
Professional roles
- Member, International Society for Bioengineering
- Member, International Society for Radioimmunotherapy
- Standing Committee Member, Lung Cancer Professional Committee, Heilongjiang Anti-Cancer Association
- Member, Lung Surgery Group, China Medical Association
Name order: in Chinese the family name comes first (Qu Changfa). Papers usually list the name as Changfa Qu or Qu C.
Selected publications
10 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): Acylation modification mediated post-translational modifications learning signature reveals ZDHHC18 promotes progression of lung adenocarcinoma by attenuating immunocyte activation. PubMed 42023227
- J Thorac Dis, 2025 (senior author): The relationship between blood biomarkers and prognosis of pathologic stage IA pure-solid non-small cell lung cancer patients. PubMed 40529775
- J Cardiothorac Surg, 2024 (senior author): Investigation of mediastinal lymph node dissection in clinical stage IA pure-solid non-small cell lung cancer patients. PubMed 38910251
- Front Genet, 2023 (senior author): Comparative analyses of salivary exosomal miRNAs for patients with or without lung cancer. PubMed 38028609
- Front Pharmacol, 2022 (senior author): Characterization of lung adenocarcinoma based on immunophenotyping and constructing an immune scoring model to predict prognosis. PubMed 36601052
- J Oncol, 2022 (senior author): Establishing a Novel Gene Signature Related to Histone Modifications for Predicting Prognosis in Lung Adenocarcinoma. PubMed 36193203
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion